{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:08:32Z","timestamp":1788804512976,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06608-4","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:39:52Z","timestamp":1788802792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u201cExceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed\/refractory multiple myeloma in the era of new immunotherapies?\u201d"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-2549","authenticated-orcid":false,"given":"Manish R.","family":"Bhise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Akotkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldip V.","family":"Gite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"6608_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00729-1","author":"K Acs","year":"2025","unstructured":"Acs K, Miettinen JJ, Sergeev P et al (2025) Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. Exp Hematol Oncol. https:\/\/doi.org\/10.1186\/s40164-025-00729-1","journal-title":"Exp Hematol Oncol"},{"key":"6608_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1691760","author":"S Aslani","year":"2025","unstructured":"Aslani S, McKay O, Lipton L, Ganju V, Croagh D (2025) Case report: two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2025.1691760","journal-title":"Front Oncol"},{"key":"6608_CR3","doi-asserted-by":"publisher","unstructured":"Farrell J, Jackson G, Scheid C (2025) Additional file 5 of Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data. https:\/\/doi.org\/10.6084\/m9.figshare.29874531","DOI":"10.6084\/m9.figshare.29874531"},{"issue":"5","key":"6608_CR4","doi-asserted-by":"publisher","first-page":"e70132","DOI":"10.1002\/hon.70132","volume":"43","author":"V Lesan","year":"2025","unstructured":"Lesan V, Odaie V, Munteanu C (2025) The role of different risk groups and treatment assignment probabilities in subgroup analysis of randomized trials. Hematol Oncol 43(5):e70132. https:\/\/doi.org\/10.1002\/hon.70132","journal-title":"Hematol Oncol"},{"key":"6608_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06659-6","author":"H Ludwig","year":"2025","unstructured":"Ludwig H, Mai EK, H\u00f6gner M, Welslau M, Waldschmidt JM (2025) Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-025-06659-6","journal-title":"Ann Hematol"},{"key":"6608_CR6","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1182\/blood-2024-198825","volume":"144","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Qasim H, Ponvilawan B et al (2024) Second primary malignancies after CAR T-cell therapy: a systemic review. Blood 144:7237. https:\/\/doi.org\/10.1182\/blood-2024-198825","journal-title":"Blood"},{"key":"6608_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06326-3","volume":"151","author":"M Talarico","year":"2025","unstructured":"Talarico M, Barbato S, Maisnar V, Delimpasi S, Puppi M, Rizzello I et al (2025) Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed\/refractory multiple myeloma in the era of new immunotherapies? J Cancer Res Clin Oncol 151:288. https:\/\/doi.org\/10.1007\/s00432-025-06326-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"6608_CR8","doi-asserted-by":"publisher","unstructured":"(2024) The impact of cytotoxic chemotherapy on somatic mutation in normal human cells. https:\/\/doi.org\/10.17863\/cam.106990","DOI":"10.17863\/cam.106990"},{"key":"6608_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.09.542","author":"AC Vecina","year":"2023","unstructured":"Vecina AC, Assis JW, Gon\u00e7alves M, Pascoal G, Rena JA, Souza R, Silva M, Vecina D, Vetorazzo L, Cliquet M (2023) Leucemia linfoide aguda como segunda neoplasia prim\u00e1ria ap\u00f3s mieloma m\u00faltiplo. Hematol Transfus Cell Ther. https:\/\/doi.org\/10.1016\/j.htct.2023.09.542","journal-title":"Hematol Transfus Cell Ther"},{"key":"6608_CR10","doi-asserted-by":"publisher","DOI":"10.57187\/s.5203","volume":"155","author":"G Waeber","year":"2025","unstructured":"Waeber G, Bassetti S, Weiler S (2025) Is it still useful to publish case reports? Schweiz Med Wochenschr 155:5203. https:\/\/doi.org\/10.57187\/s.5203","journal-title":"Schweiz Med Wochenschr"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06608-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06608-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06608-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:39:53Z","timestamp":1788802793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06608-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["6608"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06608-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"19 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this manuscript is a commentary on a previously published article.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No generative artificial intelligence tools were used in the preparation, writing, analysis, interpretation, or revision of this manuscript.","order":5,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"176"}}